# Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

- Link: https://www.thailand-business-news.com/pr-news/head-to-head-study-validates-the-clinical-advantage-of-new-generation-biased-glp-1-ecnoglutide-delivers-35-greater-weight-loss-than-semaglutide
- Published: 2026-06-08T01:30:00+07:00
- Author: PR Newswire

NEW ORLEANS, June 8, 2026 /PRNewswire/ — Hangzhou Sciwind Biosciences Co., Ltd. ("
Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering
and developing innovative therapies for metabolic diseases, today announced that
key data from a head-to-head study (SLIMMER-UP-SWITCH) evaluating ecnoglutide versus
semaglutide was presented as a Late-Breaking abstract at the 86th Scientific Sessions
of the American Diabetes Association (ADA) 2026. Interim analysis results showed
that ecnoglutide, the world’s first approved cAMP-biased GLP-1 receptor agonist,
demonstrated greater weight loss compared to semaglutide, with a 35% greater reduction
in body weight, a 20% greater reduction in waist circumference at Week 20, and nearly
twice as many patients achieving ≥10% body weight loss.

Professor Linong Ji, Director of the Department of Endocrinology at Peking University
People’s Hospital, stated that this study provides the first direct clinical evidence
validating the clinical advantages of the innovative cAMP-biased GLP-1 receptor 
agonist mechanism. By optimizing GLP-1 receptor signal transduction, it delivers
superior clinical benefits over traditional GLP-1 receptor agonists, providing high-
quality evidence-based medical evidence for the field of weight management.

**Clear Weight Loss Advantage at Week 20: 35% Greater Mean Weight Reduction vs. 
Semaglutide, ≥10% Weight Loss Response Rate Nearly Twofold Higher**

This study enrolled 163 adult patients with obesity (body mass index [BMI]≥30 kg/
m²) across 17 research centers in China. Participants were randomized 1:1 to receive
once-weekly subcutaneous injections of either ecnoglutide or semaglutide at the 
same maintenance dose of 2.4 mg¹.

Study data showed that at week 20, the least-squares mean percentage change in body
weight from baseline was -12.8% in the ecnoglutide group and -9.5% in the semaglutide
group (P<0.0001). The proportion of participants achieving ≥5% weight loss was 99%
in the ecnoglutide group versus 86% in the semaglutide group (P<0.01). The proportion
achieving ≥10% weight loss was 74% in the ecnoglutide group versus 40% in the semaglutide
group (P<0.001).

**Significant Circumference Benefits: 20% Greater Waist Circumference Reduction 
vs. Semaglutide**

In addition to potent weight loss, ecnoglutide also demonstrated remarkable advantages
in improving body circumference. Study data showed that at week 20, the mean reduction
in waist circumference from baseline was 10.5 cm in the ecnoglutide group and 8.7
cm in the semaglutide group (P<0.05), representing a 20% greater reduction for ecnoglutide.
Improvements in other circumference measures including arm circumference and neck
circumference were also superior to those of semaglutide¹.

Professor Linong Ji noted: "Central obesity, characterized by abdominal fat accumulation,
not only affects body shape but is also a key risk factor for type 2 diabetes, metabolic
syndrome and cardiovascular diseases. While effectively reducing body weight, ecnoglutide
significantly improves central obesity and local fat accumulation, optimizing body
shape while lowering the risk of related metabolic diseases."

**Nobel Prize-Winning Research Translation: Biased Mechanism Achieves Balance Between
Efficacy and Safety**

Traditional GLP-1 receptor agonists mostly adopt a "full pathway activation" mode,
which activates weight loss signaling pathways but also often activates pathways
associated with gastrointestinal adverse events and receptor desensitization, making
it difficult to balance potent weight loss and good tolerability.

Based on Nobel Prize-winning research findings^(3), ecnoglutide further contributes
the industry-wide challenge of balancing efficacy and tolerability in traditional
weight loss therapies by optimizing GLP-1 receptor signal transduction. Its safety
profile was also reaffirmed in this head-to-head study. Consistent with previous
SLIMMER study results, ecnoglutide demonstrated favorable gastrointestinal safety
^(1,2).

Dr. Hai Pan, Founder and CEO of Sciwind Biosciences, stated: "We are honored to 
present this major breakthrough at the ADA Scientific Sessions, the world’s most
influential academic conference in the global metabolic field. Better weight loss
therapies do not come from simple stacking of targets, but from precise regulation
of key biological mechanisms. The head-to-head study of ecnoglutide versus semaglutide
provides direct clinical evidence for this innovative concept, marking an important
milestone in the translation of biased agonist mechanisms from cutting-edge science
to clinical application. From Nobel Prize-level basic research to patient-accessible
clinical products, we will remain committed to scientific translation, turning more
cutting-edge scientific achievements into tangible health benefits for patients 
worldwide."

Jean-Christophe Pointeau, Global Senior Vice President and President of Pfizer China,
stated: "These new findings add to the clinical evidence that new generation biased
GLP-1 therapies in weight management and metabolic treatment can offer patients 
enhanced efficacy, tolerability and safety. As the commercialization partner for
ecnoglutide in China, Pfizer is proud to support the introduction of this therapy
and help expand access, providing new options to help people in China manage weight
in a healthy way."

**About the SLIMMER-UP-SWITCH Head-to-Head Study¹**

SLIMMER-UP-SWITCH is a multicenter, randomized, open-label Phase 2 clinical trial
conducted at 17 research centers in China, enrolling 163 adult patients with obesity(
BMI ≥30 kg/m²). Participants were randomized 1:1 to receive once-weekly subcutaneous
injections of ecnoglutide or semaglutide for a 60-week treatment period, with a 
pre-specified interim analysis conducted at Week 20. The interim analysis data of
this study has been selected as a Late Breaking abstract and presented as a poster
at the 2026 ADA Scientific Sessions.

**About the SLIMMER Study²**

The SLIMMER study is a large-scale Phase 3 clinical trial that enrolled 664 Chinese
adult subjects with overweight or obesity. In the SLIMMER study, ecnoglutide demonstrated
clinically meaningful efficacy. After 48 weeks of treatment, subjects in the highest
dose group (2.4 mg) achieved an average weight loss of 15.4%, with 92.8% of subjects
losing more than 5% of their body weight. The study also observed a significant 
reduction in waist circumference (average reduction of 12.8 cm), a 53.1% average
reduction in liver fat content in subjects with baseline fatty liver disease, and
significant improvements in multiple metabolic indicators including blood pressure,
blood lipids and blood glucose; in addition, uric acid levels decreased by an average
of 54.3 μmol/L. In the study, the treatment discontinuation rate due to adverse 
events was 2%, and the discontinuation rate due to gastrointestinal adverse events
was 0.6%.

**About Ecnoglutide **

Ecnoglutide is a cAMP-biased GLP-1 receptor agonist developed by Sciwind Biosciences
for obesity and related metabolic diseases. Pfizer has exclusive commercialization
rights for Sciwind’s injectible ecnoglutide product in Mainland China.

**About Sciwind Biosciences**

Sciwind Biosciences is a commercial-stage biopharmaceutical company, dedicated to
addressing the unmet medical needs in the field of weight management and metabolic
diseases. Sciwind has established a robust pipeline anchored by the lead asset, 
ecnoglutide (XW003). It has developed multiple proprietary technology platforms,
including biased agonist discovery platform, long-acting and oral peptide delivery
platforms, and has identified a series of drug candidates based on these core technology
platforms. Sciwind has built an extensive pipeline targeting GLP-1 and synergistic
pathways, offering both injectable and oral treatment solutions to deliver sustainable
and high-quality therapies for patients with metabolic diseases.

For more information, please visit Sciwind Biosciences’ official website: [www.sciwind.com.cn](https://www.sciwind.com.cn/)

References

 1. 2026 ADA poster 12-B. Study number SCW0502-1122
 2. Ji L, et al. Lancet Diabetes Endocrinol. 2025 Sep;13(9):777-789
 3. Mullard A. Nat Rev Drug Discov. 2023 May;22(5)347-348.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide ](http://www.prnasia.com/story/archive/4977758_AE77758_0?rand=184833)